June 03, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Bempedoic acid may prevent dangerous blood clots from forming in addition to reducing risk for major cardiovascular events vs. placebo in statin-intolerant people with prior CVD or at high risk for it, researchers reported.Bempedoic acid (Nexletol, Esperion Therapeutics) significantly reduced risk for venous thromboembolism, including both deep vein thrombosis and pulmonary embolism, compared
June 03, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Study data convince Lundbeck to push new migraine drug forward

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes

Post-Marketing Studies Document Extra VTE Risk for Baricitinib

Trial Dims Prospects for Rivaroxaban's Cardiovascular Protection in Advanced CKD

In high-risk patients without prior heart attack or stroke who underwent percutaneous coronary intervention, evolocumab reduced…

Genetic PCSK9 inhibition via base editing appeared safe and demonstrated dose-dependent, durable reductions in PCSK9 and LDL…

In adults with prior preventive migraine treatment failures, an investigational monoclonal antibody led to larger decreases in…

AstraZeneca announced the FDA approved baxdrostat for uncontrolled hypertension as add-on therapy on top of standard…

Find the latest Vascular Medicine news articles, videos, podcasts, and meeting coverage from medical experts and key opinion…

Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives